METHOD FOR DETERMINING THE RISK OF RECURRENCE OF LOCALIZED PROSTATE CANCER AFTER PERFORMING HIGH-INTENSITY FOCUSED ULTRASONIC ABLATION Russian patent published in 2019 - IPC G01N33/48 G01N33/483 G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncourology, particularly to determining the risk of recurrent localized prostate cancer following high-intensity focused ultrasonic ablation – HIFU. That is ensured by assessing the preoperative concentration of the initial prostate-specific antigen – PSA in blood in ng/ml, followed by histopathological examination of the prostate biopsy materials, determining the number of positive columns in the biopsy material – pos cores, the presence and severity of perineural invasion – peri, perineural invasion in the apex of the prostate – Ap.Peri, in the morphological examination, the tumor volume is determined – Vtum, indicating the percentage of the tissue affected by the tumor, the presence of the G3 pattern on the Gleason scale, the presence of prostatic intraepithelial neoplasia (PIN), in immunohistological analysis of prostate biopsy materials, presence and intensity of expression of p53 and bcl-2 in tumor cells is evaluated, which is a risk factor of recurrent localized prostate cancer, then each factor is set its rank, as well as its diagnostic coefficient, then the patient is determined by the corresponding sum of diagnostic coefficients and with a sum exceeding the value of the differential separation point cut off 1.5 points, high risk of recurrent localized prostate cancer in the next three years after high-intensity focused ultrasonic ablation is considered.

EFFECT: invention provides more accurate prediction of the therapeutic effect of localized prostate cancer by HIFU.

1 cl, 2 dwg, 4 tbl, 2 ex